Supplementary Online Content


eResults

eFigure 1. Distribution of BCVA Changes From Baseline at Months 6, 9, 12, and 24 Among Early 10-Letter Responders

eFigure 2. Anatomical Responses Over Time in 10-Letter Responders

This supplementary material has been provided by the authors to give readers additional information about their work.
**eResults**

**10-Letter Responders**
Baseline BCVA for early and delayed 10-letter responders was 52.5 and 55.2 letters, respectively ($P=.028$). Early 10-letter responders experienced initial BCVA gains +17.4 letters from baseline at month 3 that were maintained through month 12 (+18.2 letters) and month 24 (+17.4 letters) (Figure 1, top right). Initial BCVA response to ranibizumab treatment in delayed 10-letter responders was slow to month 3 (+4.3 letters), with improvement throughout year 1 approaching that of early responders by month 12 (+15.0 letters) and maintained at month 24 (+13.6 letters) (Figure 1, middle right). The median time to first gain of 10 letters was 1.0 and 4.9 months in early and delayed 10-letter responders, respectively. Approximately 80% of delayed 10-letter responders achieved 10-letter gains by month 8 (Figure 1, bottom right).

**Anatomical Response in 10-Letter Responders**
Early and delayed 10-letter responders experienced decreases from baseline to month 3 in mean CFT (baseline vs month 3, 362.0 vs 188.2 µm and 311.9 vs 187.1 µm, respectively), mean total CNV area (baseline vs month 3, 2.8 vs 1.4 DA and 3.4 vs 1.7 DA, respectively), mean total lesion area (baseline vs month 3, 2.9 vs 1.7 DA and 3.6 vs 2.2 DA, respectively), and proportion of patients with presence of blood (baseline vs month 3, 88.1% vs 27.6% and 83.6% vs 28.6%, respectively) (eFigure 2). As for 15-letter responders, these measures were further decreased in early and delayed 10-letter responders at month 12 and maintained to month 24.
**eFigure 1.** Distribution of BCVA Changes From Baseline at Months 6, 9, 12, and 24 Among Early 10-Letter Responders

All BCVA changes refer to the study eye and are compared with baseline. Observed data are shown.

*Number of patients having the indicated BCVA gain.

Abbreviations: BCVA, best-corrected visual acuity; PRN, as needed.
eFigure 2. Anatomical Responses Over Time in 10-Letter Responders

A.

B.

C.

D.

All treatment groups are pooled. (A) CFT. (B) Total CNV area. (C) Percent of patients with presence of blood. (D) Total lesion area. Observed data and ±2 standard errors of the mean (A, B, D) or 95% confidence intervals (C) are shown.

Abbreviations: CFT, central foveal thickness; CNV, choroidal neovascularization; DA, disc area.